UniProt P04587
HIV-1 Protease (P04587)
HIV-1 Protease (UniProt P04587), EC 3.4.23.16: 120 experimental structures on GenesisL1, 7 ligands bound, 1 pocket. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P04587
- Protein
- HIV-1 Protease
- EC
- 3.4.23.16
- Experimental structures
- 120
- Predicted models
- 0
- Ligands
- 7
- Pockets
- 1 · 1 record with a druggable one
Structures
120 records of P04587 in the MolNFT archive: 120 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1BDL | HIV-1 (2:31-37) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1BDL | HIV-1 (2:31-37) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1BDQ | HIV-1 (2:31-37, 47, 82) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1BDQ | HIV-1 (2:31-37, 47, 82) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1BDR | HIV-1 (2: 31, 33-37) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1BDR | HIV-1 (2: 31, 33-37) protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1FEJ | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FEJ | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FF0 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FF0 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FFF | Structural implications of drug resistant mutants of HIV-1 protease : high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FFF | Structural implications of drug resistant mutants of HIV-1 protease : high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FFI | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FFI | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FG6 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FG6 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FG8 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FG8 | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FGC | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1FGC | Structural implications of drug resistant mutants of HIV-1 protease: high resolution crystal… | x-ray diffraction | C, D | — | — |
| 1G2K | HIV-1 protease with cyclic sulfamide inhibitor, AHA047 | x-ray diffraction | A, B | — | — |
| 1G2K | HIV-1 protease with cyclic sulfamide inhibitor, AHA047 | x-ray diffraction | A, B | — | — |
| 1HPV | Crystal structure of HIV-1 protease in complex with vx-478, a potent and orally bioavailable… | x-ray diffraction | A, B | — | — |
| 1HPV | Crystal structure of HIV-1 protease in complex with vx-478, a potent and orally bioavailable… | x-ray diffraction | A, B | — | — |
| 1HVJ | Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of… | x-ray diffraction | A, B | — | — |
| 1HVJ | Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of… | x-ray diffraction | A, B | — | — |
| 1HVS | Structural basis of drug resistance for the V82A mutant of HIV-1 protease: backbone flexibility and… | x-ray diffraction | A, B | — | — |
| 1HVS | Structural basis of drug resistance for the V82A mutant of HIV-1 protease: backbone flexibility and… | x-ray diffraction | A, B | — | — |
| 1K1T | Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance | x-ray diffraction | A, B | — | — |
| 1K1T | Combining mutations in HIV-1 protease to understand mechanisms of resistance | x-ray diffraction | A, B | — | — |
| 1K1U | Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance | x-ray diffraction | A, B | — | — |
| 1K1U | Combining mutations in HIV-1 protease to understand mechanisms of resistance | x-ray diffraction | A, B | — | — |
| 1K2B | Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance | x-ray diffraction | A, B | — | — |
| 1K2B | Combining mutations in HIV-1 protease to understand mechanisms of resistance | x-ray diffraction | A, B | — | — |
| 1K2C | Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance | x-ray diffraction | A, B | — | — |
| 1K2C | Combining mutations in HIV-1 protease to understand mechanisms of resistance | x-ray diffraction | A, B | — | — |
| 1Q9P | Solution structure of the mature HIV-1 protease monomer | solution nmr | A | — | — |
| 1Q9P | Solution structure of the mature HIV-1 protease monomer | solution nmr | A | — | — |
| 1TCX | HIV triple mutant protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1TCX | HIV triple mutant protease complexed with inhibitor SB203386 | x-ray diffraction | A, B | — | — |
| 1WJE | Solution structure of H12C mutant of the N-terminal zn binding domain of HIV-1 integrase complexed… | solution nmr | A, B | — | — |
| 1WJE | Solution structure of H12C mutant of the N-terminal zn binding domain of HIV-1 integrase complexed… | solution nmr | A, B | — | — |
| 1WJF | Solution structure of H12C mutant of the N-terminal zn binding domain of HIV-1 integrase complexed… | solution nmr | A, B | — | — |
| 1WJF | Solution structure of H12C mutant of the N-terminal zn binding domain of HIV-1 integrase complexed… | solution nmr | A, B | — | — |
| 2AOC | Crystal structure analysis of HIV-1 protease mutant I84V with a substrate analog P2-NC | x-ray diffraction | A, B | — | — |
| 2AOC | Crystal structure analysis of HIV-1 protease mutant I84V with a substrate analog P2-nc | x-ray diffraction | A, B | — | — |
| 2AOD | Crystal structure analysis of HIV-1 protease with a substrate analog P2-NC | x-ray diffraction | A, B | — | — |
| 2AOD | Crystal structure analysis of HIV-1 protease with a substrate analog P2-nc | x-ray diffraction | A, B | — | — |
| 2AOE | crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog CA-P2 | x-ray diffraction | A, B | — | — |
| 2AOE | Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog ca-P2 | x-ray diffraction | A, B | — | — |
| 2AOF | Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P1-P6 | x-ray diffraction | A, B | — | — |
| 2AOF | Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P1-P6 | x-ray diffraction | A, B | — | — |
| 2AOG | Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P2-NC | x-ray diffraction | A, B | — | — |
| 2AOG | Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P2-nc | x-ray diffraction | A, B | — | — |
| 2AOH | Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P6-PR | x-ray diffraction | A, B | — | — |
| 2AOH | Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P6-pr | x-ray diffraction | A, B | — | — |
| 2AOI | Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6 | x-ray diffraction | A, B | — | — |
| 2AOI | Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6 | x-ray diffraction | A, B | — | — |
| 2AOJ | Crystal structure analysis of HIV-1 protease with a substrate analog P6-PR | x-ray diffraction | A, B | — | — |
| 2AOJ | Crystal structure analysis of HIV-1 protease with a substrate analog P6-pr | x-ray diffraction | A, B | — | — |
60 records more on the page itself.
Ligands
- CL · Chloride ion · in 8 records
- CKV · N-(3-fluoro-2-{2-[(2S,5S)-5-methyl-1-(phenylsulfonyl) piperazin-2-yl]ethyl}phenyl)-3,3-bis(4-fluorophenyl) propanamide · in 2 records
- CKY · N-(3-fluoro-2-{2-[(2S,6S)-6-methyl-1-(phenylsulfonyl) piperazin-2-yl]ethyl}phenyl)-3,3-bis(4-fluorophenyl) propanamide · in 2 records
- CKD · (S)-N-(3-fluoro-2-(2-(1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide · in 1 record
- CKM · N-(3-fluoro-2-{2-[(2S,6R)-6-methyl-1-(phenylsulfonyl) piperazin-2-yl]ethyl}phenyl)-3,3-bis(4-fluorophenyl) propanamide · in 1 record
- CKS · N-(3-fluoro-2-{2-[(2S,5R)-5-methyl-1-(phenylsulfonyl) piperazin-2-yl]ethyl}phenyl)-3,3-bis(4-fluorophenyl) propanamide · in 1 record
- CN4 · N-(2-{2-[(6R,9S)-2,2-dioxo-2lambda~6~-thia-1,7-diazabicyclo[4.3.1]decan-9-yl]ethyl}-3-fluorophenyl)-3,3-bis(4-fluorophenyl)propanamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.